Your browser doesn't support javascript.
loading
A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali, Liaqat; Saxena, Gauri; Jones, Meleri; Leisegang, Georgia R; Gammon, Luke; Gnanapavan, Sharmilee; Giovannoni, Gavin; Schmierer, Klaus; Baker, David; Kang, Angray S.
Affiliation
  • Ali L; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Saxena G; Department of Biological Sciences, National University of Medical Sciences (NUMS), Rawalpindi 46000, Pakistan.
  • Jones M; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Leisegang GR; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Gammon L; Centre for Oral Immunobiology & Regenerative Medicine, Institute of Dentistry, Barts & the London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
  • Gnanapavan S; Barts & The London School of Medicine & Dentistry, Blizard Institute, Queen Mary University of London, Whitechapel, London, UK.
  • Giovannoni G; BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
  • Schmierer K; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, UK.
  • Baker D; BartsMS, Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, E1 2AT, UK.
  • Kang AS; Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, UK.
Biotechniques ; 68(4): 185-190, 2020 04.
Article in En | MEDLINE | ID: mdl-32096651
ABSTRACT

Aim:

The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles.

Results:

Alemtuzumab-Alexa Fluor 488 conjugate binding to the CHO-CD52 cell surface was inhibited by anti-alemtuzumab antibodies.

Conclusion:

In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunoassay / Cytological Techniques / Antibodies, Neutralizing / Alemtuzumab Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunoassay / Cytological Techniques / Antibodies, Neutralizing / Alemtuzumab Type of study: Diagnostic_studies Limits: Animals / Humans Language: En Year: 2020 Type: Article